Sugi Predict

Sugi Predict / Compounds / SCHEMBL14945133

SCHEMBL14945133

SCHEMBL14945133

CCOC(=O)c1sc2[nH]c(=O)n(C(C)(C)C(=O)OC(C)(C)C)c(=O)c2c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.41
▸ RXFP1 Q9HBX9 2/20 0.41
▸ PPARG P37231 1/20 0.41
▸ NCOA2 Q15596 1/20 0.41
▸ ALDH1A1 P00352 7/20 0.41
▸ KDM4E B2RXH2 4/20 0.39
▸ GAA P10253 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ TSHR P16473 2/20 0.37
▸ RAB9A P51151 3/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ PDE4A P27815 2/20 0.36
▸ PDE4B Q07343 2/20 0.36
▸ PDE4C Q08493 2/20 0.36
▸ PDE4D Q08499 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14945478 0.92 MAPT (0.41) MAPTRXFP1PPARGNCOA2ALDH1A1
SCHEMBL14945486 0.87 MAPT (0.44) MAPTRXFP1PPARGNCOA2ALDH1A1
SCHEMBL14945132 0.86 ALDH1A1 (0.39) MAPTRXFP1ALDH1A1KDM4EGAA
SCHEMBL18909862 0.86 MAPT (0.39) MAPTRXFP1PPARGNCOA2ALDH1A1
SCHEMBL21570674 0.84 MAPT (0.41) MAPTRXFP1PPARGNCOA2ALDH1A1
SCHEMBL14945487 0.84 MAPT (0.41) MAPTRXFP1PPARGNCOA2ALDH1A1
SCHEMBL14945512 0.83 KMT2A (0.43) MAPTRXFP1PPARGNCOA2ALDH1A1
SCHEMBL14945492 0.83 ALDH1A1 (0.31) MAPTRXFP1ALDH1A1
SCHEMBL20867639 0.83 ALDH1A1 (0.31) MAPTRXFP1ALDH1A1
SCHEMBL18959775 0.83 KMT2A (0.46) MAPTRXFP1PPARGNCOA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107629069-B Preparation method of acetyl coenzyme A carboxylase inhibitor 中国药科大学 2023-01-24 — — CN disclosed
US-10941158-B2 Pyrazole ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2021-03-09 — — US disclosed
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF SCHRÖDINGER, INC. 2020-04-02 — — US disclosed
US-10472374-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2019-11-12 — — US disclosed
EP-3329919-B1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO LLC (US) 2019-11-06 — — EP disclosed
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2019-01-17 — — US disclosed
WO-2018161008-A1 PROCESSES FOR THE PREPARATION OF FUNGICIDAL COMPOUNDS GILEAD APOLLO, LLC (US) 2018-09-07 — — WO disclosed
WO-2017091600-A9 PYRAZOLE ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2018-07-19 — — WO disclosed
EP-3329919-A1 ACC INHIBITORS AND USES THEREOF Gilead Apollo, LLC (US) 2018-06-06 — — EP disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
WO-2017091602-A1 ESTER ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2017-06-01 — — WO disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
WO-2013071169-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MAPT 2490/4885RXFP1 4538/4885PPARG 641/4885
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MAPT 2490/4885RXFP1 4538/4885PPARG 641/4885
US-10472374-B2 ACC inhibitors and uses thereof ACACA, ACACB, ACAT2 MAPT 2490/4885RXFP1 4538/4885PPARG 641/4885
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MAPT 2490/4885RXFP1 4538/4885PPARG 641/4885
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MAPT 2490/4885RXFP1 4538/4885PPARG 641/4885
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 MAPT 2490/4885RXFP1 4538/4885PPARG 641/4885
US-10941158-B2 Pyrazole ACC inhibitors and uses thereof ACACA, ACACB, PC MAPT 2266/4885RXFP1 4449/4885PPARG 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.